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Risk factors and the natural history of
accelerated knee osteoarthritis: a narrative
review
Jeffrey B. Driban1* , Matthew S. Harkey1,2, Mary F. Barbe3, Robert J. Ward4, James W. MacKay5,6, Julie E. Davis7,
Bing Lu8, Lori Lyn Price9,10, Charles B. Eaton11, Grace H. Lo12,13 and Timothy E. McAlindon1
Abstract
Background: Osteoarthritis is generally a slowly progressive disorder. However, at least 1 in 7 people with incident
knee osteoarthritis develop an abrupt progression to advanced-stage radiographic disease, many within 12 months.
We summarize what is known – primarily based on findings from the Osteoarthritis Initiative – about the risk factors
and natural history of accelerated knee osteoarthritis (AKOA) – defined as a transition from no radiographic knee
osteoarthritis to advanced-stage disease < 4 years – and put these findings in context with typical osteoarthritis
(slowly progressing disease), aging, prior case reports/series, and relevant animal models.
Summary: Risk factors in the 2 to 4 years before radiographic manifestation of AKOA (onset) include older age,
higher body mass index, altered joint alignment, contralateral osteoarthritis, greater pre-radiographic disease burden
(structural, symptoms, and function), or low fasting glucose. One to 2 years before AKOA onset people often exhibit
rapid articular cartilage loss, larger bone marrow lesions and effusion-synovitis, more meniscal pathology, slower
chair-stand or walking pace, and increased global impact of arthritis than adults with typical knee osteoarthritis.
Increased joint symptoms predispose a person to new joint trauma, which for someone who develops AKOA is
often characterized by a destabilizing meniscal tear (e.g., radial or root tear). One in 7 people with AKOA onset
subsequently receive a knee replacement during a 9-year period. The median time from any increase in
radiographic severity to knee replacement is only 2.3 years. Despite some similarities, AKOA is different than other
rapidly progressive arthropathies and collapsing these phenomena together or extracting results from one type of
osteoarthritis to another should be avoided until further research comparing these types of osteoarthritis is
conducted. Animal models that induce meniscal damage in the presence of other risk factors or create an
incongruent distribution of loading on joints create an accelerated form of osteoarthritis compared to other models
and may offer insights into AKOA.
Conclusion: Accelerated knee osteoarthritis is unique from typical knee osteoarthritis. The incidence of AKOA in the
Osteoarthritis Initiative and Chingford Study is substantial. AKOA needs to be taken into account and studied in
epidemiologic studies and clinical trials.
Keywords: Knee, Osteoarthritis, Phenotype, Risk factors, Natural history, Magnetic resonance imaging, Radiography,
Meniscus
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Background
Knee osteoarthritis is typically a slowly progressive dis-
order. However, approximately 3.4% of adults develop
radiographic evidence of accelerated knee osteoarthritis
(AKOA) over 4 years [1, 2]. Therefore, at least 1 in 7
cases of incident knee osteoarthritis develop AKOA [1,
2]. We define AKOA as a process characterized by the
rapid onset and progression from pre-radiographic dis-
ease to advanced-stage radiographic disease in less than
4 years (Kellgren-Lawrence [KL] grades = 0 or 1 to KL =
3 or 4) [1, 3, 4]. For the purpose of this review we will
define the “onset” of AKOA as the first visit with radio-
graphic evidence of advanced-stage radiographic disease.
Individuals that develop AKOA typically progress from
no or doubtful knee osteoarthritis (KL 0 to 1) to definite
joint space narrowing and osteophyte (KL = 3) [5]. Two
out of 3 adults that develop AKOA will experience this
sudden onset and progression (KL 0 or 1 to KL 3 or 4)
within 1 year [1, 3–5].
Adults with AKOA represent an important proportion
of adults with incident knee osteoarthritis. For example,
at least 3 years before radiographic onset adults with in-
cident AKOA have greater pain and disability compared
to adults with a typical, gradual onset of knee osteoarth-
ritis (KL 0 to 1, KL 0 to 2, or KL 1 to 2 over 4 years) [5,
6]. Furthermore, while very few people who develop typ-
ical knee osteoarthritis receive a knee replacement over
8 years (0.3%), more than 1 in 14 (7%) adults with
AKOA undergo a knee arthroplasty within 2.3 years after
initial signs of radiographic progression [7]. Including
these adults in studies with those who develop typical
knee osteoarthritis may yield misleading results in clin-
ical trials and epidemiological studies [3]. Unfortunately,
there are no comprehensive reviews to synthesize the
risk factors and natural history for AKOA, as well as
how AKOA compares with the current paradigm of typ-
ical knee osteoarthritis, aging (no radiographic knee
osteoarthritis and no KL change over 4 years), and rap-
idly progressive forms of osteoarthritis. This latter point
is particularly relevant because clinicians and researchers
often interchange the terms accelerated and rapidly pro-
gressive osteoarthritis despite important differences be-
tween these disorders. The purpose of this narrative
review is to summarize recent evidence from the Osteo-
arthritis Initiative about the risk factors and natural his-
tory of accelerated knee osteoarthritis (AKOA) – defined
as a transition between no radiographic knee osteoarth-
ritis to advanced-stage disease within 4 years – and put
these new findings in context with typical osteoarthritis,
aging, prior case reports/series, and relevant animal
models. We acknowledge that the definition of typical
knee osteoarthritis may be susceptible to misclassifica-
tion because of a reliance on subtle changes in KL
grades. However, we believe this definition has construct
validity because the people with typical knee osteoarth-
ritis differ from those without knee osteoarthritis based
on reporting more knee symptoms the year before dis-
ease onset [6], reporting a knee injury more often before
radiographic changes (a key risk factor for osteoarthritis)
[1], and having more meniscal pathology [8].
To achieve our goal, we will start by reviewing the nat-
ural history of AKOA and its risk factors. The natural
history will be divided into 3 phases: 1) 2 or more years
before radiographic osteoarthritis onset, 2) 1 to 2 years
before radiographic osteoarthritis onset, and 3) less than
1 year before radiographic onset. Within each phase, we
will describe the clinical and structural changes that
characterize each phase in comparison to adults with
typical knee osteoarthritis or no knee osteoarthritis (rep-
resentative of age-related changes). After summarizing
the natural history of AKOA, we will describe the clin-
ical consequences of AKOA, strategies to classify adults
at risk for AKOA, and put AKOA into context with
rapidly progressive osteoarthritis and destructive
arthropathies.
Natural history of accelerated knee osteoarthritis
and its risk factors
Numerous factors may contribute to AKOA and help
people identify who will develop it. Similar to typical
knee osteoarthritis, older age and body mass index
(BMI) are related to AKOA onset [1, 9, 10]. However,
two subgroups are at greater risk for AKOA: 1) individ-
uals < 65 years of age with BMI > 32.5 kg/m2 and 2) indi-
viduals > 65 years of age that were typically overweight
or obese with BMI < 35 kg/m2 (only 27% had BMI < 25
kg/m2) [10–12]. Greater age and BMI may contribute to
the onset of AKOA through pathways related to hyper-
glycemia and elevated inflammation. However, contrary
to this hypothesis, glycated serum protein concentra-
tions, a biomarker of glucose homeostasis, associated
with the subsequent onset of typical knee osteoarthritis
but not AKOA [13]. There are also no statistical associa-
tions between serum concentrations of C-reactive pro-
tein or glucose and AKOA onset over the subsequent 4
years to those measurements [13]. It remains unknown
if a change in biomarkers of systemic inflammation or
glucose homeostasis occurs as people develop pre-
radiographic structural changes that antedate radio-
graphic disease onset.
Certain biomechanical factors may also contribute to
AKOA. While the presence of static knee malalignment
does not significantly differ between individuals who will
develop AKOA or typical knee osteoarthritis, greater
coronal tibial slope (describing the slope of the tibial
plateau relative to a perpendicular line to the long axis
of the tibia) is related with a greater odds of incident
AKOA but not typical knee osteoarthritis when
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compared to adults without knee osteoarthritis. How-
ever, this relationship was only present among people
who had a varus or valgus static malalignment [14].
Hence, a joint may tolerate aberrant coronal tibial slopes
in isolation but become susceptible to failure when
stressed by combining altered coronal tibial slope with
static malalignment (i.e., varus or valgus malalignment).
2 or more years before radiographic osteoarthritis onset
Clinical
Individuals destined to develop AKOA are more likely to
report more knee pain and knee-specific disability, as
well as walk slower than adults who will develop typical
knee osteoarthritis up to 3 years in advance of disease
onset [5].
Structural alterations
Magnetic resonance images may reveal why people 2
years in advance of radiographic disease onset are more
likely to report greater pain and dysfunction than indi-
viduals who develop typical knee osteoarthritis. For ex-
ample, adults with infrapatellar fat pad signal-intensity
alteration or large effusion-synovitis volume, assessed
with magnetic resonance imaging, have roughly twice
the odds of developing AKOA onset over the subsequent
four years [15]. At least 2 years before radiographic on-
set, people who develop AKOA have greater effusion-
synovitis volume compared with those who developed
typical knee osteoarthritis [16]. Furthermore, adults who
develop AKOA are more likely to have infrapatellar fat
pad signal-intensity alteration than those with no knee
osteoarthritis [16]. Effusion-synovitis volume and infra-
patellar fat pad signal-intensity alteration may be reflect-
ive of local inflammation [17] and at least moderately
related to knee pain [18–22].
Effusion-synovitis can be both a result of other joint
damage or significant stress to a joint [22] or contribute
to further aberrant structural changes [23]. Therefore,
effusion-synovitis may be a key contributor that perpetu-
ates a vicious cycle defined by joint damage causing
effusion-synovitis that leads to worsening pathology and
ultimately leads to the accelerated joint decline that is
observed in AKOA.
Joint symptoms and effusion-synovitis during this early
phase coincide with other structural alterations. For ex-
ample, a possible sign that the joint experiences abnor-
mal biomechanical loading early in the disease process is
that degenerative cruciate ligaments [11, 15], meniscal
pathology [15], and thicker medial femoral cartilage
(possibly cartilage swelling) [8] are pathologic features
on magnetic resonance imaging that may discriminate
people who will develop AKOA over the subsequent 2
to 4 years. These pathologic findings may be caused by
abnormal arthrokinematics (e.g., laxity) or contribute to
abnormal arthrokinematics that lead to local inflamma-
tion. In the first scenario, a person may have altered
arthrokinematics leading to these pathologic findings be-
cause of acquired poor movement patterns or poor
neuromuscular control secondary to a large effusion-
synovitis volume [24–26]. In the second scenario, the
degenerative cruciate ligaments could introduce rota-
tional or antero-posterior knee instability and increased
external adduction moments during walking, which con-
tributes to meniscal pathology and large effusion-
synovitis volumes [27]. These early risk factors or
markers of AKOA may suggest we should explore the
benefit of early use of arthrocentesis, anti-inflammatory
therapies, or physical rehabilitation focused on neuro-
muscular control for people at risk for AKOA.
At 2 years prior to radiographic onset, people who de-
veloped AKOA have significantly higher odds of having
meniscal pathology than controls, especially destabilizing
meniscal tears (odds ratio ~ 4.7) [8]. Destabilizing menis-
cal tears compromise meniscal function and load distri-
bution properties [28, 29] and consist of a radial tear
(including a root tear) or complex tear, which almost al-
ways includes a radial component [8]. The adults who
develop AKOA are also more likely to have meniscal
damage in 2 or more regions (66% vs 30%), any medial
meniscal pathology (excluding extrusion; 72% vs 39%),
and medial meniscal extrusion (20% vs 6%), compared
with adults with no knee osteoarthritis over the next 4
years [8].
These early findings highlight that adults who develop
AKOA experience greater preradiographic disease bur-
den than their peers who develop typical or no knee
osteoarthritis over the next 4 years. It remains unclear
why the joint is experiencing excessive disease burden
during this early phase. The joint may be susceptible to
these early pathologic changes because of a genetic pre-
disposition or developmental susceptibility that leaves
their tissues ill-prepared to handle joint loading, or the
joint is exposed to excessive overloading with inadequate
recovery that leads to increased local inflammation and
aberrant tissue changes [30]. While clarifying the eti-
ology of these early changes could yield novel prevention
strategies, it is essential to also take steps to identify
people without radiographic knee osteoarthritis that re-
port greater joint symptoms and may have magnetic res-
onance imaging evidence of greater disease burden to
help prevent accelerated disease onset and progression.
1 to 2 years before radiographic osteoarthritis onset
Clinical
Between 2 to 1 year before disease onset people who de-
velop AKOA are more likely to report greater knee pain
than earlier assessments [5]. Chair-stand pace and self-
reported global impact of arthritis also start to worsen
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among those who develop AKOA while those with typ-
ical knee osteoarthritis stay the same or improve slightly
[5]. These worsening symptoms correspond to the start
of a dramatic rate of changes within the joint.
Structural alterations
During the 2 years before radiographic disease onset,
adults who develop AKOA have, on average, a 4.6
times greater increase in effusion-synovitis volume
compared with their peers with typical knee osteo-
arthritis [16]. Additionally, they experience, on aver-
age, a 13 times greater increase in bone marrow
lesion volume and a greater loss of articular cartilage
than adults with typical knee osteoarthritis [8]. Unlike
typical knee osteoarthritis, which may be conceptual-
ized with focal cartilage damage, adults who develop
AKOA experience diffuse cartilage changes through-
out the knee [31]. Overall, these early changes
characterize the start of a downward slope towards
joint failure. It will be helpful to learn whether an
intervention could halt or slow this progression or if
they have already passed a point of no return.
Less than 1 year before radiographic onset
Clinical
Within the 12-months before disease onset, people who
develop AKOA (31%) or typical knee osteoarthritis
(21%) are more likely to report frequent use of medica-
tion for pain, aching, or stiffness compared with those
with no knee osteoarthritis (10%) [6]. Despite the fre-
quent use of medication to manage symptoms, people
who develop AKOA or typical knee osteoarthritis during
the next 12 months report greater symptoms in most ac-
tivities than those without incident knee osteoarthritis.
More specifically, people who develop AKOA are more
likely to report greater difficulty with lying down, pain
with straightening the knee, pain walking, daily knee
pain, and frequent knee swelling compared with peers
who will develop typical knee osteoarthritis [6].
Structural alterations
This peak in prodromal symptoms corresponds to con-
tinued worsening throughout the knee; including wors-
ening bone marrow lesions, increasing effusion-synovitis
volumes, and more frequent occurrence of infrapatellar
fat pad signal-intensity alterations, meniscal damage in 2
or more regions, any medial meniscal pathology or
extrusion, or lateral meniscal extrusion than adults with
either typical or no knee osteoarthritis [8, 16]. These
changes may be secondary to diffuse differences in tissue
composition or secondary to joint instability.
A new knee injury – especially within 1 year before
radiographic onset
If a susceptible knee has large effusion-synovitis or de-
generative cruciate ligaments that contribute to altered
lower extremity biomechanics, then it is no surprise that
these adults also report more knee injuries than their
peers. Specifically, a single new injury may be a critical
event that leads to joint failure or characterizes the onset
of AKOA [1, 9, 32]. A history of a knee injury several
years before the onset of AKOA is unrelated to disease
onset [1, 9]. However, an injury in the year or two before
incident knee osteoarthritis is more common among
adults that develop AKOA or typical knee osteoarthritis
than those who do not develop knee osteoarthritis [1].
Furthermore, a knee injury may be especially likely to
lead to AKOA among normal weight and older individ-
uals (65 years or older) or overweight-obese individuals
(Fig. 1) [10]. Among people with incident AKOA, 26%
were older or overweight/obese and reported a new in-
jury in the year before developing disease onset. In con-
trast, only 8 and 3% of people with incident typical knee
osteoarthritis or no knee osteoarthritis were older or
overweight/obese and reported a new injury (Fig. 1) [10].
Hence, a new knee injury to a joint already susceptible
because of other risk factors may increase the risk of an
accelerated rate of joint failure.
The interaction between other risk factors and a knee
injury is consistent with evidence from the destabilizing
medial meniscal (DMM) mouse model. The DMM model
is a surgical model that relies on destabilizing the medial
meniscus to mimic human clinical meniscal injury, espe-
cially a destabilizing meniscal tear [33, 34]. The natural
history of disease progression after DMM is similar to
spontaneous onset [33, 35]; however, greater age [36, 37]
and high-fat diets [38] are risk factors for accelerated dis-
ease onset after DMM. Furthermore, while a sex-age
interaction is not reported among studies of AKOA, there
is evidence that this interaction may be relevant in the
DMM model. With a DMM model, orchiectomized male
mice (lower testosterone) had less severe osteoarthritis
than other males while ovariectomized female mice (lower
sex hormones) had greater disease severity than other fe-
males. The interaction between injury, sex, sex hormones,
and age may explain why simplistic analyses of sex differ-
ences in AKOA are null and, therefore, a more nuanced
study may be needed [34].
We must be cautious about relying solely on self-
reported injury because adults who develop AKOA may
fail to perceive a traumatic event as a knee injury [32].
For example, among people who develop AKOA that
failed to report an injury, almost 40% had distinct struc-
tural changes on magnetic resonance images, typically
incident medial meniscal pathology [32]. Hence, it be-
came critical to understand the key structures that
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experienced trauma around the time of disease onset.
Ultimately, destabilizing meniscal tears (i.e., radial tears,
root tears, complex tears) and trauma to the subchon-
dral bone characterized the trauma that led to or charac-
terized the onset of AKOA instead of typical knee
osteoarthritis [8, 32, 39, 40].
By the time people present with AKOA, they are > 7
times more likely to have a destabilizing meniscal tear
than those without AKOA [8]. Furthermore, over 90% of
adults with AKOA have meniscal damage in 2 or more
regions, 85% have medial meniscal pathology, and 77%
of individuals with AKOA have meniscal extrusion [8].
It is paramount that we identify people prior to this
devasting trauma and strive to prevent trauma, which is
likely the tipping point from which a joint is unable to
recover and ultimately leads to a quick onset of joint
failure. Collectively, this evidence supports a call that if a
patient is referred to physical therapy for knee pain they
may benefit from establishing a goal to prevent a new
joint injury that could either be the catalyst for joint fail-
ure or define a pivotal moment in the process of joint
failure.
Summary of natural history
In summary, the natural history of incident AKOA can
be conceptualized as three phases (Fig. 2). Starting at
least 2 years in advance of radiographic onset, adults
with AKOA may experience greater effusion-synovitis,
thicker articular cartilage, diffuse meniscal pathology (in-
cluding destabilizing meniscal tears), and degenerative
changes in the cruciate ligaments and extensor mechan-
ism. Hence, during this early phase, a joint is already ex-
periencing greater preradiographic disease burden than
their peers, which may explain why they report more
prodromal symptoms than those who develop typical
knee osteoarthritis. The subsequent 12-month phase is
defined by a dramatic rate of worsening in effusion-
synovitis, bone marrow lesions, and articular cartilage
(Fig. 2).
Within 12months before radiographic onset, adults
with AKOA report more joint symptoms, frequent use
of pain medication, frequent knee swelling, and daily
knee pain compared with those who develop typical
knee osteoarthritis. The greater knee pain could contrib-
ute to a new knee injury, which is often characterized by
a destabilizing meniscal tear. The joint trauma may be a
triggering event in a joint with an impaired ability to
heal, which ultimately leads to joint failure. The compro-
mised ability to heal in response to an injury may com-
plement evidence from young adult rats performing a
high-repetition, high-force reaching and lever pulling
task [30, 41]. This model may suggest that the damage-
Fig. 1 The distribution people across groups that develop accelerated, typical, or no knee osteoarthritis (KOA). The distribution of subsets of
people in the Osteoarthritis Initiative defined by age, body mass index, and injury across groups that develop accelerated, typical, or no knee
osteoarthritis (KOA) [10]. The percentages in the data table are based on the percent of people with accelerated, typical, or no KOA that are in
each subset (each column adds to ~ 100% due to rounding) [10]
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repair theory may be relevant to trabecular changes
[42] and that damage accumulates in the bone if the
loading is so high that self-repair mechanisms cannot
keep pace with the level of damage or overloading-
induced bone resorption. When rats perform the
high-repetition, high-force task for 18 weeks, they ex-
hibit several catabolic indices in trabeculae in their
distal radial metaphyses, including decreased trabecu-
lar bone volume, increased woven bone, osteoclast
numbers, microcracks and osteocyte apoptosis, com-
pared to control rats. The loss of trabecular bone vol-
ume enhances brittleness and increases fracture risk
[43]. These catabolic bone changes with high demand
tasks are also consistent with the fatigue-failure the-
ory for musculoskeletal disorder injuries [44]. Hence,
overloading a knee joint beyond its capacity to repair
may contribute to the accumulation of bone damage,
which could explain why adults with AKOA develop
larger bone marrow lesions and are more likely to de-
velop attrition or subchondral insufficiency fractures
than their peers [8, 39].
Clinical consequences of accelerated knee
osteoarthritis
At an individual level, we’ve described how adults with
AKOA experience greater symptoms and functional im-
pairments starting up to 3 years prior to radiographic dis-
ease onset. This complements findings that over the first
8 years of the Osteoarthritis Initiative, people who develop
AKOA are more likely to report receiving arthroscopic
knee surgery, intra-articular injections (i.e., hyaluronic
acid, corticosteroids), and nonsteroidal anti-inflammatory
drugs (over the counter or prescription) than people who
develop typical or no knee osteoarthritis [45]. Even prior
to the onset of radiographic evidence of AKOA, people
who will develop AKOA are more likely to use certain
prescription analgesics (e.g., acetaminophen, celecoxib, as-
pirin) and receive arthroscopic knee surgery than those
who will develop typical knee osteoarthritis [45].
The greater personal burden of AKOA is further
highlighted by the high rate of knee replacements. While
most people who started the Osteoarthritis Initiative
without radiographic knee osteoarthritis did not receive
Fig. 2 Phases of the Natural History of Accelerated Knee Osteoarthritis
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a knee replacement over the first 9 years of the study (≤
1%), almost 1 in 7 knees with AKOA received a knee
replacement during that period [7]. Furthermore, the
median time from any increase in radiographic severity
(change in KL grade) to knee replacement was 2.3 years
(range 0.3 to 7.3 years) compared with the few knees
with typical osteoarthritis that received a knee replace-
ment (3.0 years; range 1.7 to 4.2 years) [7]. Adults with
AKOA experience significant disease burden and have
only a short window of opportunity to intervene, with 1
in 14 knees receiving a knee replacement in less than
2.3 years after the first evidence of radiographic
progression.
Another concern is that our perception of osteoarth-
ritis may be biased by our failure to account for people
with AKOA. Within the Osteoarthritis Initiative, AKOA
accounts for more than 1 in 5 cases of incident knee
osteoarthritis [1]. Hence, factors that have a strong rela-
tionship with AKOA, but not typical knee osteoarthritis,
may still appear associated with knee osteoarthritis over-
all. For example, excluding people with incident AKOA
from analyses that defined incident knee osteoarthritis
as at least a 2-point increase in radiographic severity led
to smaller effect estimates (Cohen’s d [46]) when com-
paring cases of incident disease to controls: knee pain
over time (d = 0.41 for everyone, d = 0.14 after excluding
AKOA) or recent knee injury (OR = 5.4 for everyone,
OR = 4.0 after excluding AKOA) [3]. It is essential that
we critically assess our current conceptual model of knee
osteoarthritis by accounting for differences among
phenotypes or clinically relevant subsets (e.g., AKOA).
Furthermore, we need to consider the consequences of
recruiting people with AKOA into clinical trials. Separ-
ate trials may be necessary for AKOA and other types of
knee osteoarthritis given AKOA has a distinct natural
history defined by the onset of a destabilizing meniscal
tear in a joint already susceptible to failure. A critical
question is whether people with AKOA will respond dif-
ferently to therapeutic interventions when compared to
those with typical osteoarthritis.
Classifying adults at risk for accelerated knee
osteoarthritis
To develop prevention strategies and clinical trials
for adults at risk for AKOA, it is crucial to identify
who will likely develop AKOA. Riddle and colleagues
developed a prediction rule to estimate the chance
of incident AKOA over the subsequent 5 years and
found that the presence of possible knee osteoarth-
ritis (KL = 1), contralateral knee osteoarthritis,
greater BMI, and joint symptoms (total Western On-
tario and McMaster Universities Osteoarthritis Index
[WOMAC] score) increased the chance of someone
developing AKOA [4]. While this prediction rule
provided valuable insights into identifying people at
risk for AKOA, it inadequately addressed the com-
plex interactions among the risk factors, and it
lacked MR-based structural features that may help
classify individuals at risk for AKOA. Hence, we
used classification and regression tree (CART) ana-
lyses, which can 1) identify the most statistically im-
portant factors and the associated cut points to most
efficiently differentiate groups for classifying individ-
uals, and 2) account for complex interactions that
may optimize the ability to classify individuals at risk
for AKOA. Furthermore, we used the CART analyses
to explore if MR-based structural findings could help
classify people at high risk for AKOA (54 people de-
veloped AKOA and 108 sex-matched Osteoarthritis
Initiative participants). There is consistent evidence
that age, fasting glucose concentrations, and static
knee alignment were statistically important clinical
factors to consider when classifying people at risk
for incident AKOA [11, 12]. Effusion-synovitis vol-
ume and cruciate ligament degeneration may also be
statistically important for classifying people at risk
for AKOA over the subsequent 4 years [11]; however,
adding data from magnetic resonance imaging (e.g.,
quantitative effusion-synovitis, cartilage damage,
bone marrow lesions; semiquantitative assessments
of menisci, tendons, ligaments) failed to improve the
ability to classify adults who develop AKOA over the
models with only clinical measures (Table 1). Fur-
thermore, the models failed to explain the majority
of the variance that contribute to someone being
classified as incident AKOA or not. Hence, we are
either missing a major factor that contributes to
classifying people with AKOA or there are numerous
factors that contribute a little to the classification.
Going forward, it will be important to better under-
stand the earliest phases of AKOA to develop
strategies to identify people at risk for or with early-
stage AKOA.
Table 1 Performance of Classification Rules for People who Will
Develop AKOA Over the Subsequent 4 Years
Clinical Modela Clinical + MRI Modelb
Specificity 0.82 0.90
Sensitivity 0.70 0.62
Explained Variance (%) 41% 39%
Note: AKOA = accelerated knee osteoarthritis, MRI = magnetic
resonance imaging
aThe final clinical classification tree included age, body mass index, serum
glucose concentrations, femorotibial alignment angle, serum glycated serum
protein concentrations, WOMAC knee-related function score, and coronal tibial
slope angle [11]
bThe final clinical+MRI classification tree included body mass index, serum
glucose concentrations, effusion-synovitis volume, presence of cruciate
ligament degeneration, and coronal tibial slope angle [11]
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Accelerated knee osteoarthritis within the context
of rapidly progressive osteoarthritis and
destructive arthropathies
Numerous terms have been used during the last 60 years
in the medical literature to describe a dramatic change
in joint health; including rapidly progressive disease, rap-
idly destructive disease, accelerated degeneration,
massive osteolysis, rapid chondrolysis, among others.
The heterogeneity in nomenclature reflects uncertainty
about how to classify rapidly destructive forms of osteo-
arthritis and their underlying mechanisms.
It is informative to reassess the existing literature and
consider how various definitions may impact the re-
ported epidemiology of rapidly progressive or acceler-
ated osteoarthritis. For example, in Table 2, we offer
several definitions of accelerated or rapidly progressive
osteoarthritis and how the incidence using these defini-
tions vary from 0 to 22% within the Osteoarthritis
Initiative.
Recently, two classifications for rapidly progressive
osteoarthritis have been adopted to characterize the
rapid joint destruction observed in clinical trials for anti-
nerve growth factor (NGF) agents [51, 52]. Rapid
progressive osteoarthritis type 1 is similar to an early
definition provided by Lequesne [50] that requires more
than 2mm of loss in joint space width in less than one
year. Rapid progressive osteoarthritis type 2 is defined by
abnormal bone loss or destruction (e.g., osteolysis) [51,
52]. Within the context of the anti-NGF clinical trials,
these types of rapid progressive osteoarthritis usually
(but not always) manifest in a joint in which osteoarth-
ritis was already present [53]. In contrast, research fo-
cused on AKOA has focused on incident disease [4, 40,
54]. While these differences may be consequent on the
differences in research design and setting, it remains un-
clear whether AKOA and rapid progressive osteoarthritis
type 1 are separate or overlapping entities. A clear dis-
tinction between AKOA and rapid progressive osteo-
arthritis is that adults with AKOA rarely experience the
rate of joint space loss nor the dramatic bone destruc-
tion observed with rapid progressive osteoarthritis. For
example, no one with AKOA in the Osteoarthritis Initia-
tive experienced more than 2mm of loss in joint space
width in less than one year nor abnormal bone loss or
destruction. Furthermore, rapid progressive osteoarth-
ritis is often described in knees, hips, or shoulders [46,
50, 53, 55, 56]. However, accelerated osteoarthritis is pri-
marily observed in the knee and, to a lesser extent, the
hand. Therefore, it is unclear how rapid progressive
osteoarthritis at large ball-and-socket joints relates to
findings at the knee.
Despite differences between AKOA and rapid progres-
sive osteoarthritis, some interesting similarities may be
worth exploring further. Both are more common among
older adults and may be antedated by certain analgesic
medications [45]. Furthermore, people who develop
AKOA or rapid progressive osteoarthritis have early evi-
dence of cartilage degradation followed by an extreme
rate of articular cartilage loss [8, 31, 57] and early evi-
dence of inflammation [11, 15, 16, 57]. Finally, 12% of
knees that develop AKOA experience attrition or sub-
chondral fractures [8] and 35% of people who develop
accelerated hand osteoarthritis develop new central ero-
sions in other hand joints [58]. While people with accel-
erated osteoarthritis never experience the dramatic bone
destruction or collapse seen with some types of rapid
progressive osteoarthritis it may be beneficial to further
explore the role of bone changes in each type of
osteoarthritis.
Until we reach greater clarity about the pathogeneses
of these subsets of osteoarthritis, it may be inappropriate
to conflate them in clinical practice or research studies.
Furthermore, we need to be cautious about collapsing
these phenomena together or extracting results from
one type of osteoarthritis to another. Further studying
the similarities and differences between AKOA and
other forms of rapidly progressive osteoarthritis may
yield new insights into these subsets of osteoarthritis.
Conclusions
Accelerated osteoarthritis is distinct from typical osteo-
arthritis. The incidence of AKOA is likely greater than
Table 2 Frequency of Accelerated or Rapid KOA Using Previously Reported Definitions Among Adults without Radiographic KOA at
OAI Baseline
Term Radiographic Change Time Frame Incidence in OAI
Accelerated OA [1, 3, 4] KL 0 or 1 to KL 3 or 4 4 or 5 years 7.2%
Rapid Radiographic Change [47] KL 0 or 1 then KL change > 2 4 or 5 years 12.4%
Fast JSW Loss [48] > 0.25 mm medial JSW change 1 year 15.5 to 22.1%
Rapid Progressors [49] > 1.05 mm medial JSW change 1 year 0.4 to 0.8%
Rapid Destructive Arthrosis [50] > 2 mm JSW change or 50% narrowing 1 year 0%
Rapid Progressive OA Type 1 [46, 47] > 2.00 mm JSW change 1 year 0%
Rapid Progressive OA Type 2 [46, 47] abnormal bone loss or destruction short period of time 0%
Note: KOA knee osteoarthritis, OAI Osteoarthritis Initiative, OA osteoarthritis, JSW joint space width
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commonly perceived and could have a profound impact
on epidemiologic studies and clinical trials. There is an
urgent need to consider this subset of osteoarthritis
when performing clinical research and to create standard
nomenclature for the array of arthropathies that may be
related but distinct from AKOA.
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